litlas
Log inCreate account

Nicola Gökbuget

Active 1996–2025

99
Papers
21,360
Citations
69
h-index
95
i10-index

Citations

Citations per year for Nicola Gökbuget1998: 1 citations1999: 4 citations2000: 9 citations2001: 1 citations2002: 23 citations2003: 25 citations2004: 26 citations2005: 29 citations2006: 21 citations2007: 32 citations2008: 43 citations2009: 65 citations2010: 40 citations2011: 46 citations2012: 119 citations2013: 120 citations2014: 126 citations2015: 199 citations2016: 245 citations2017: 238 citations2018: 236 citations2019: 878 citations2020: 867 citations2021: 780 citations2022: 613 citations2023: 555 citations2024: 1,045 citations2025: 509 citations2026: 3 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,892 citing papers, 26.3% of this breakdownGermany: 721 citing papers, 10% of this breakdownItaly: 497 citing papers, 6.9% of this breakdownChina: 448 citing papers, 6.2% of this breakdownUnited Kingdom: 401 citing papers, 5.6% of this breakdownFrance: 365 citing papers, 5.1% of this breakdownSpain: 292 citing papers, 4.1% of this breakdownNetherlands: 232 citing papers, 3.2% of this breakdownCanada: 193 citing papers, 2.7% of this breakdownSwitzerland: 182 citing papers, 2.5% of this breakdownAustralia: 174 citing papers, 2.4% of this breakdownJapan: 126 citing papers, 1.7% of this breakdown
0%26.3%Other 23.3%

Institutions

Fields

  • Medicine85.9%
  • Biochemistry, Genetics and Molecular Biology8.2%
  • Immunology and Microbiology3.9%
  • Mathematics0.4%
  • Computer Science0.3%
  • Materials Science0.3%
  • Other1%

Topics

  • Acute Lymphoblastic Leukemia research12%
  • CAR-T cell therapy research11.6%
  • Acute Myeloid Leukemia Research9.2%
  • Chronic Myeloid Leukemia Treatments6.1%
  • Lymphoma Diagnosis and Treatment4.4%
  • Monoclonal and Polyclonal Antibodies Research3.9%
  • Other52.8%

Coauthors

All papers

Open in search
  1. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

    Authors: Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso‐Ramos, Jörge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström‐Lindberg, Gabriela Hobbs, Ronald Hoffman, Elias Jabbour, Jean‐Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte M. Niemeyer, Olatoyosi Odenike, Seishi Ogawa, Alberto Órfão, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching‐Hon Pui, Jerald P. Radich, Andreas Reiter, Marı́a Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt‐Graeff, Akiko Shimamura, Jorge Sierra, Wendy Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei‐Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi - Blood 2022 cited by 2,693

  2. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

    Authors: Hagop Kantarjian, Anthony S. Stein, Nicola Gökbuget, Adele K. Fielding, Andre C. Schuh, Josep‐María Ribera, Andrew H. Wei, Hervé Dombret, Robin Foà, Renato Bassan, Önder Arslan, Miguel Á. Sanz, Julie Bergeron, Fatih Demırkan, Ewa Lech‐Marańda, Alessandro Rambaldi, Xavier Thomas, Heinz‐August Horst, Monika Brüggemann, Wolfgang Hiddemann, Brent L. Wood, A. Fleishman, Dirk Nagorsen, Christopher P. Holland, Zachary Zimmerman, Max S. Topp - New England Journal of Medicine 2017 cited by 2,090

  3. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

    Authors: Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes, Giovanni Martinelli, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan O’Brien, Kongming Wang, Tao Wang, M. Luisa Paccagnella, Barbara Sleight, Erik Vandendries, Anjali S. Advani - New England Journal of Medicine 2016 cited by 1,373

  4. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

    Authors: Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Christoph Faul, H. Diedrich, Max S. Topp, Monika Brüggemann, Heinz‐August Horst, Violaine Havelange, Julia Stieglmaier, Hendrik Wessels, Vincent Haddad, Jonathan E. Benjamin, Gerhard Zugmaier, Dirk Nagorsen, Ralf C. Bargou - Blood 2018 cited by 845

  5. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

    Authors: Max S. Topp, Nicola Gökbuget, Anthony S. Stein, Gerhard Zugmaier, Susan O’Brien, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Leonard T. Heffner, Richard A Larson, Svenja Neumann, Robin Foà, Mark R. Litzow, Josep‐María Ribera, Alessandro Rambaldi, Gary J. Schiller, Monika Brüggemann, Heinz A. Horst, Chris Holland, Catherine Jia, Tapan Maniar, Birgit Huber, Dirk Nagorsen, Stephen J. Forman, Hagop M. Kantarjian - The Lancet Oncology 2014 cited by 1,259

  6. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

    Authors: Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Susan O’Brien, Elias Jabbour, Tao Wang, Jane Liang White, Barbara Sleight, Erik Vandendries, Anjali S. Advani - Cancer 2019 cited by 329

  7. Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

    Authors: Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier, Petra Klappers, Matthias Stelljes, Svenja Neumann, Andreas Viardot, Reinhard Marks, H. Diedrich, Christoph Faul, Albrecht Reichle, Heinz‐August Horst, Monika Brüggemann, Dorothea Wessiepe, Chris Holland, Shilpa Alekar, Noemi Mergen, Hermann Einsele, Dieter Hoelzer, Ralf C. Bargou - Journal of Clinical Oncology 2014 cited by 659

  8. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome–Negative B-Precursor ALL

    Authors: Matthias Stelljes, Simon Raffel, Nael Alakel, Ralph Wäsch, Mustafa Kondakci, Sebastian Scholl, Andreas Rank, Mathias Hänel, Bernd M. Spriewald, Maher Hanoun, Sonja Martin, Katjana Schwab, Hubert Serve, Lena Reiser, Julian Knaden, Heike Pfeifer, Julia Marx, Tim Sauer, Wolfgang E. Berdel, Georg Lenz, Monika Brüggemann, Nicola Gökbuget, Klaus Wethmar - Journal of Clinical Oncology 2023 cited by 77

  9. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

    Authors: Philippe Rousselot, marie Magdelaine Coude, Nicola Gökbuget, Carlo Gambacorti‐Passerini, Sandrine Hayette, Jean‐Michel Cayuela, Françoise Huguet, Thibaut Leguay, Patrice Chevallier, Célia Salanoubat, Caroline Bonmati, Magda Alexis, Mathilde Hunault, Sylvie Glaisner, Philippe Agapé, Christian Berthou, Éric Jourdan, José Fernandes, Laurent Sutton, Anne Banos, Oumédaly Reman, Bruno Lioure, Xavier Thomas, Norbert Ifrah, Mårina Lafage‐Pochitaloff, Anne Bornand, Laure Morisset, Valérie Robin, Heike Pfeifer, André Delannoy, Josep‐María Ribera, Renato Bassan, Marc Delord, Dieter Hoelzer, Hervé Dombret, Oliver G. Ottmann - Blood 2016 cited by 326

  10. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

    Authors: Nicola Gökbuget, Michael Kneba, Thorsten Raff, Heiko Trautmann, C. R. Bartram, Renate Arnold, Rainer Fietkau, Mathias Freund, Arnold Ganser, Wolfgang Ludwig, Georg Maschmeyer, Harald Rieder, Stefan Schwartz, Hubert Serve, Eckhard Thiel, Monika Brüggemann, Dieter Hoelzer - Blood 2012 cited by 493

  11. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

    Authors: Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, Oliver G. Ottmann, Nicola Gökbuget, Max S. Topp, Adele K. Fielding, Alessandro Rambaldi, Ellen K. Ritchie, Cristina Papayannidis, Lulu Ren Sterling, Jonathan Benjamin, Anthony S. Stein - Journal of Clinical Oncology 2017 cited by 446

  12. Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

    Authors: Max S. Topp, Peter Kufer, Nicola Gökbuget, Mariele Goebeler, Matthias Klinger, Svenja Neumann, Heinz-A. Horst, Thorsten Raff, Andreas Viardot, Mathias Schmid, Matthias Stelljes, Markus Schaich, Evelyn Degenhard, R Köhne-Volland, Monika Brüggemann, Oliver G. Ottmann, Heike Pfeifer, Thomas Burmeister, Dirk Nagorsen, Margit Schmidt, Ralf Lutterbuese, Carsten Reinhardt, Patrick A. Baeuerle, Michael Kneba, Hermann Einsele, Gert Riethmüller, Dieter Hoelzer, Gerhard Zugmaier, Ralf C. Bargou - Journal of Clinical Oncology 2011 cited by 913

  13. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study

    Authors: Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, Oliver G. Ottmann, Nicola Gökbuget, Alessandro Rambaldi, Ellen K. Ritchie, Cristina Papayannidis, Catherine Tuglus, Joan Morris, Anthony S. Stein - European Journal of Cancer 2021 cited by 93

  14. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

    Authors: Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele K. Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver G. Ottmann, Anita W. Rijneveld, Philippe Rousselot, Josep‐María Ribera, Renato Bassan - Blood 2024 cited by 76

  15. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

    Authors: Nicola Gökbuget, Daniel Stanze, Joachim Beck, H. Diedrich, Heinz‐August Horst, Andreas Hüttmann, Guido Kobbe, Karl‐Anton Kreuzer, Lothar Leimer, Albrecht Reichle, Markus Schaich, Stefan Schwartz, Hubert Serve, Michael Starck, Matthias Stelljes, Reingard Stuhlmann, Andreas Viardot, Knut Wendelin, Mathias Freund, Dieter Hoelzer - Blood 2012 cited by 465

  16. Management of ALL in adults: 2024 ELN recommendations from a European expert panel

    Authors: Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele K. Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver G. Ottmann, Anita W. Rijneveld, Philippe Rousselot, Josep‐María Ribera, Renato Bassan - Blood 2024 cited by 109

  17. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

    Authors: Daniel J. DeAngelo, Anjali S. Advani, David I. Marks, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Elias Jabbour, Akil Merchant, Tao Wang, Erik Vandendries, Alexander Neuhof, Hagop M. Kantarjian, Susan O’Brien - Blood Cancer Journal 2020 cited by 68

  18. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia

    Authors: Nicola Gökbuget, Gerhard Zugmaier, Hervé Dombret, Anthony S. Stein, Massimiliano Bonifacio, Carlos Graux, Christoph Faul, Monika Brüggemann, Kate Taylor, Noemi Mergen, Albrecht Reichle, Heinz‐August Horst, Violaine Havelange, Max S. Topp, Ralf C. Bargou - Leukemia & lymphoma/Leukemia and lymphoma 2020 cited by 87

  19. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

    Authors: Maria‐Luisa Schubert, Anita Schmitt, Angela Hückelhoven‐Krauss, Brigitte Neuber, Alexander Kunz, Philip Waldhoff, Dominik Vonficht, Schayan Yousefian, Lea Jopp‐Saile, Lei Wang, Felix Korell, Anna Keib, Birgit Michels, Dominik Haas, Tim Sauer, Patrick Derigs, Andreas E. Kulozik, Joachim B. Kunz, Petra Pavel, Sascha Laier, Patrick Wuchter, Johann W. Schmier, Gesine Bug, Fabian Lang, Nicola Gökbuget, Jochen Casper, Martin Görner, Jürgen Finke, Andreas Neubauer, Mark Ringhoffer, Denise Wolleschak, Monika Brüggemann, Simon Haas, Anthony D. Ho, Carsten Müller‐Tidow, Peter Dreger, Michael Schmitt - Journal of Hematology & Oncology 2023 cited by 36

  20. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

    Authors: Monika Brüggemann, Thorsten Raff, Thomas Flohr, Nicola Gökbuget, Makoto Nakao, J Droese, Silke Lüschen, Christiane Pott, Matthias Ritgen, Urban Scheuring, Heinz‐August Horst, Eckhard Thiel, Dieter Hoelzer, Claus R. Bartram, Michael Kneba - Blood 2005 cited by 537

  21. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders

    Authors: Marco Ladetto, Monika Brüggemann, Luigia Monitillo, Simone Ferrero, François Pépin, Daniela Drandi, Diego Barbero, Antonio Palumbo, Roberto Passera, Mario Boccadoro, Matthias Ritgen, Nicola Gökbuget, Jianbiao Zheng, Victoria Carlton, Heiko Trautmann, Malek Faham, Christiane Pott - Leukemia 2013 cited by 305

  22. Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis

    Authors: Tobias Herold, Stephanie Schneider, Klaus H. Metzeler, Martín Neumann, Luise Hartmann, Kathryn G. Roberts, Nikola P. Konstandin, Philipp A. Greif, Kathrin Bräundl, Bianka Ksienzyk, Natalia Huk, Irene C. Schneider, Evelyn Zellmeier, Vindi Jurinović, Ulrich Mansmann, Wolfgang Hiddemann, Charles G. Mullighan, Stefan K. Bohlander, Karsten Spiekermann, Dieter Hoelzer, Monika Brüggemann, Claudia D. Baldus, Martin Dreyling, Nicola Gökbuget - Haematologica 2016 cited by 164

  23. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia

    Authors: Wendy Stock, Giovanni Martinelli, Matthias Stelljes, Daniel J. DeAngelo, Nicola Gökbuget, Anjali S. Advani, Susan O’Brien, Michaela Liedtke, Akil Merchant, Ryan D. Cassaday, Tao Wang, Hui Zhang, Erik Vandendries, Elias Jabbour, David I. Marks, Hagop M. Kantarjian - Cancer 2020 cited by 75

  24. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

    Authors: Matthias Klinger, Christian Brandl, Gerhard Zugmaier, Youssef Hijazi, Ralf C. Bargou, Max S. Topp, Nicola Gökbuget, Svenja Neumann, Mariele Goebeler, Andreas Viardot, Matthias Stelljes, Monika Brüggemann, Dieter Hoelzer, Evelyn Degenhard, Dirk Nagorsen, Patrick A. Baeuerle, Andreas Wolf, Peter Kufer - Blood 2012 cited by 463